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Abstract: Estrogen signaling plays an important role in pituitary development and function. In
sensitive rat or mice strains of both sexes, estrogen treatments promote lactotropic cell proliferation and
induce the formation of pituitary adenomas (dominantly prolactin or growth-hormone-secreting ones).
In male patients receiving estrogen, treatment does not necessarily result in pituitary hyperplasia,
hyperprolactinemia or adenoma development. In this review, we comprehensively analyze the
mechanisms of estrogen action upon their application in male animal models comparing it with
available data in human subjects. Sex-specific molecular targets of estrogen action in lactotropic
(PRL) cells are highlighted in the context of their proliferative and secretory activity. In addition,
putative effects of estradiol on the cellular/tumor microenvironment and the contribution of postnatal
pituitary progenitor/stem cells and transdifferentiation processes to prolactinoma development have
been analyzed. Finally, estrogen-induced morphological and hormone-secreting changes in pituitary
thyrotropic (TSH) and adrenocorticotropic (ACTH) cells are discussed, as well as the putative role
of the thyroid and/or glucocorticoid hormones in prolactinoma development, based on the current
scarce literature.
Keywords: pituitary gland; estrogen; prolactinoma; men; rat; microenvironment; folliculo-stellate
cells; prolactin; thyroid-stimulating hormone; adrenocorticotropic hormone
1. Introduction
The anterior pituitary is the principal regulator of endocrine homeostasis and is populated by
at least five highly differentiated hormone-producing cell types, through which this gland responds
to central and peripheral signals. Terminal differentiation and proliferation of lactotropic cells, but
also gonadotrophic lineage during embryonic development, is regulated by estrogens [1,2]. In adults,
estrogens are able to induce formation of pituitary adenomas in sensitive rat or mice strains, most of
which are functional, prolactin (PRL)- and/or growth-hormone (GH)-secreting tumors [3]. In humans,
prolonged estrogen treatment does not necessarily result in hyperprolactinemia, pituitary hyperplasia
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or progression to prolactinomas [4,5]. On the other hand, some case reports indicate the development
of prolactinoma in male-to-female transsexuals who are subjected to estrogen treatment [6].
Similar prevalence, but a higher incidence of pituitary prolactinoma formation is observed in
women at a younger age in comparison with men [7,8] and disappears after menopause [9]. Moreover,
male patients have a higher serum PRL level and larger tumor volume in comparison with female
patients with prolactinoma [10,11]. Typically, prolactinomas have a more aggressive clinical behavior
in men [12,13]. To date, these sex-related differences have not been fully understood. Most recent basic
research, using single-cell genomic approaches, has shed some light on sex-specific expression of genes
in lactotropic cells that may, at least in part, underlie the observed differences [14–16].
The presence of estradiol in males has been known for over 90 years, and it is now well-accepted
that estradiol plays an essential role in male physiology [17,18]. Moreover, various estradiol-based
pharmacotherapeutics, as well as estrogen-like natural compounds, have found application in men,
either in targeted therapy of specific pathological conditions or in alleviation of a whole range of health
issues. Androgen deprivation therapy, which is achieved by medical or surgical castration as well as
by estrogen therapy, has been widely used in the treatment of prostate cancer for many decades [19].
Moreover, male-to-female transsexual patients use estrogen therapy to adapt their physical bodies
to those of the female sex [20,21]. Though estrogen therapy can induce gynecomastia in men, its
transdermal or parenteral route of administration was reported to reduce the risk of toxicity [22,23].
Studies examining prolactinoma development in transsexual patients receiving combined antiandrogen
and estrogen treatments are confounding, indicating both prolactinoma development [20,24] and/or
no influence of estrogen [4]. Clinical data describing the consequences of cross-sexual hormonal
treatments on the pituitary, particularly in cases of uncontrolled self-administration or exposure at
older age are still lacking [25].
In this review, we analyze the key mechanisms through which estrogen treatments may affect the
proliferative and secretory activity of pituitary lactotropic cells in male rodent models, by emphasizing
sensitive molecular targets of estrogen action expressed in a sex-related manner. Moreover, putative
effects of estradiol on the cellular microenvironment and the contribution of postnatal pituitary
progenitor/stem cells and transdifferentiation processes to prolactinoma development have also
been analyzed. Special attention is given to the less well-studied. pituitary thyrotropic (TSH)
and adrenocorticotropic (ACTH) cells in this context and to the putative role of the thyroid and
glucocorticoid hormones in prolactinoma development.
2. Estrogen Signaling in the Anterior Pituitary and Prolactinoma Development in Males
Pituitary adenomas are mainly benign tumors with a favorable prognosis that arise from the
anterior pituitary. However, they may be clinically relevant, causing a variety of clinical symptoms
and associated syndromes due to the overproduction of hormones, and/or have invasive behavior [26],
leading to significant morbidity and mortality [27].
The molecular mechanisms underlying the generation of pituitary adenomas are largely unknown,
but it is clear that estrogen plays an important role in their pathogenesis in both sexes [28]. In
males, endogenous estradiol production requires aromatase (CYP19A1), a ubiquitous cytochrome P450
reductase enzyme, which catalyzes local tissue conversion of androgens to estrogens. Aromatase
expression has been confirmed in rodent and human pituitaries [29–31]. Studies of aromatase
overexpression and knockout transgenic mice models confirmed that estradiol is largely responsible
for the maintenance of the population of lactotropic cells in males [32,33], apart from playing an
essential role in the hypothalamus–pituitary regulation of testicular and associated functions [18,34].
With regard to aromatase expression in pituitary adenomas and its possible association with tumor
subtype, sex and/or tumor size, the results are still confounding [29,35–37] and await further
multimethodological confirmation and testing. Of note, clinical management of hypogonadism
in men with macroprolactinoma, which was refractive to dopamine agonists, required aromatase
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inhibitor treatment in addition to testosterone replacement, to prevent the secondary rise in PRL and,
finally, the potential for tumor enlargement [38].
Regarding the pituitary, there are several proposed mechanisms explaining estrogen action on
the development of lactotropic hyperplasia, hyperprolactinemia and prolactinoma (summarized in
Figure 1). They include direct and indirect effects of estradiol on already-differentiated lactotropic cells
to enhance their proliferative and secretory activity and potentiated transdifferentiation from another
lineage-related hormone-producing cell type, as well as stimulation of pituitary stem/progenitor cell
differentiation in the direction of a lactotropic cell line. Moreover, estrogen may induce changes
in the cellular microenvironment by contributing to the recruitment of immune cells and affecting
the synthesis of pituitary growth factors and cytokines, thus contributing to tumor initiation and
promotion. Effects of estrogen on the hypothalamic regulation of PRL cells (including TRH, dopamine,
somatostatin, and other signaling pathways) have been, inter alia, described by other authors [39].
Figure 1. Proposed cellular and molecular targets of estrogen treatment action that contribute
to pituitary lactotropic (PRL) cell hyperplasia, hyperprolactinemia and prolactinoma development.
Estrogen may affect already-differentiated PRL cells, stem/progenitor cells, lineage-related cells and cells
comprising the microenvironment. Transcriptional regulation of the following genes is mainly associated
with tumorigenic action of estrogen in the pituitary: pituitary tumor transforming gene (PTTG);
Myc; aldehyde dehydrogenase 1A1 (ALDH1A1); D2R, dopamine D2 receptor; mitogen-activated
protein kinases (MAPK); vascular endothelial growth factor (VEGF); fibroblast growth factor 2
(FGF2); transforming growth factor β (TGFβ) and other growth factors and cytokines, such as ILs,
interleukines [15,16,40–53].
3. Effects of Estradiol on Differentiated Lactotropic Cells in the Anterior Pituitary
Pituitary lactotropic cells of both sexes are typical estrogen-responsive cells. Estrogen treatment
in vivo and in vitro induces their proliferation and PRL secretion (Figure 1), while long-term treatments
lead to the formation of PRL-secreting tumors in sensitive rodent strains [3,40,54]. The rapid
development of prolactinoma in response to prolonged estrogen treatment makes rodent models of
sensitive strain useful for studying tumorigenesis.
We examined effects of male estrogenisation on the pituitary and downstream elements of the
endocrine system using orchidectomized (Orx) Wistar rats of young-adult- (2–3 months old) and
middle age (15–16 months old) [55,56]. The administered dose of estradiol dipropionate (s.c. injection
of 0.0625 mg/kg b.w./day during three weeks; Orx+E) had a beneficial bone-protective effect [57].
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Irrespectively of age, estradiol treatment induced a significant increase in pituitary weight [55,56],
indicating preserved estrogen sensitivity with advancing age. Hypertrophy and hyperplasia of
PRL-immunopositive cells were observed in Orx+E middle-aged males [55], as illustrated in Figure 2.
Increased immunohistochemical (IHC) expression of vascular endothelial growth factor A (VEGFA),
a promoter of angiogenesis, and more prominent vasculature were clearly visible upon estradiol
treatment (Figure 2, Table 1).
Figure 2. Representative micrographs of immunohistochemically (IHC) or histochemically stained
anterior pituitary sections of orchidectomized (Orx) and estradiol-treated orchidectomized (Orx+E)
middle-aged rats. Hypertrophy and hyperplasia of prolactin-immunopositive cells (PRL, red arrows;
adopted from our previous publication [55] and reprinted by permission of the Licensors - publishers
Elsevier (Licence number 4774000297301)), stronger vascular endothelial growth factor A (VEGFA)
immunopositivity, more abundant blood vessels (red arrows, Novelli histochemical staining) and
lower nuclear estrogen receptor α immunopositivity (red arrows, ERα), respectively, are observable
after estradiol treatment. Micrographs were obtained according to the same procedures described
in our earlier papers [55]. Briefly, for IHC characterization of anterior pituitary tissue, the primary
rabbit antisera directed against PRL (Abcam, Cambridge, UK; 1:200), VEGFA (Abcam, Cambridge, UK;
1:100) or ERα (1:100; Santa Cruz Biotechnology), were applied overnight at 4 ◦C. Swine anti-rabbit
IgG- horseradish peroxidase (HRP; Dakopatts, Glostrup, Denmark; 1:100) was applied as a secondary
antiserum for 1 h, while visualization was performed using diaminobenzidine tetrahydrochloride
(DAB; Dakopatts, Glostrup, Denmark) at concentrations suggested by the manufacturer. Sections
were counter-stained with hematoxylin and mounted in DPX medium (Sigma-Aldrich, Barcelona,
Spain). For Novelli histochemical staining, sections were incubated in hot 1 N HCl (60 ◦C, 3 min),
followed by staining in 1% acid fuchsin (Fluka Chemie AG, Buchs, Switzerland; 30 s) and 1% light
green (Sigma-Aldrich, St. Louis, MO, USA; 3 min), respectively. In between, the slides were washed in
PBS (for Nowelly, distilled water), and after the last step, mounted in DPX (Sigma-Aldrich, Barcelona,
Spain). Scale bar is shown in the right corner.
Int. J. Mol. Sci. 2020, 21, 2024 5 of 21
Table 1. The effects of estradiol application on relevant anterior pituitary parameters in orchidectomized
middle-aged rats (Orx).
Measured Parameter Orx+E vs.Orx
Pituitary weight ↑
VEGFA immunopositivity ↑
PRL immunopositivity ↑
ERα immunopositivity ↑
S100β immunopositivity ↓
Pituitary GH immunopositivity ↑
Pituitary ACTH immunopositivity ↑
Pituitary TSH immunopositivity ↓
Serum PRL ↑
Serum GH ↑
Serum ACTH ↑
Serum TSH n.s.
Serum corticosterone n.s.
Serum L-thyroxine n.s.
VEGFA, vascular endothelial growth factor A; PRL, prolactin; ERα, estrogen receptor α; GH, growth hormone;
ACTH, adrenocorticotropic hormone; TSH, thyroid-stimulating hormone.
In human and rodent pituitary, nuclear estrogen receptor (ER) α plays a major role in the
physiological regulation of lactotropic-cell secretory and mitotic activity, whereas in growth hormone
(GH)-producing cells, both ERα and β are of importance [58,59]. With regard to sex-related differences,
the number of lactotropic cells and the expression and secretion of PRL are higher in females than in
males, both in rodents and humans [41,60,61]. Analyses of a transgenic mouse line that lacks androgen
receptors in the pituitary gland showed that androgens and androgen receptor (AR)-mediated signaling
in the pituitary also contribute to PRL maintenance and suppression of abnormal PRL production in
males [62]. Fletcher et al. [16] used transcriptomic (and other relevant) analyses in rats and showed
that lactotropic cells contain the largest number of sex-dominant genes. Interestingly, these authors
reported mRNA and protein expression of retinoic-acid-synthesizing enzyme aldehyde dehydrogenase
1A1 (ALDH1A1 or RALDH1), only in lactotropic cells from males but not from females, and in
folliculo-stellate cells (FS) from both sexes [16]. This enzyme catalyzes the conversion of 9-cis-retinal to
9-cis-retinoic acid, which increases the expression of dopamine receptor type 2 (DR2) in normal and
pituitary tumors [63,64]. In line with this, promotion of lactotropic cell secretion and proliferation in
adults is associated with reduced expression of retinoic-acid-synthesizing enzyme ALDH1, indicating its
involvement in this process. Interestingly, ALDH1 was reported to have AR binding properties [65], but
at the same time, its gene and protein expression were reported to be downregulated by 17β-estradiol
treatment (Figure 1) via ERα pathway in male rodents [42]. Further research of estrogen–androgen
interconnections may explain some of the complexities of regulation of lactotropic cells observed in
the male.
Aside from its normal physiology, ERα-mediated signaling is important for development of the
pituitary prolactinomas and may also be involved in increased aggressiveness of lactotropic tumors in
men [15] (Figure 3). Estrogen was the first-discovered inducer of pituitary tumor transforming gene
(Pttg) through its nuclear ERα, a well-known proto-oncogene whose aberrant accumulation is known to
cause genetic instability that could underlie cancer development [43] (Figure 1). PTTG interacts with a
wide variety of genes and molecules related to survival, mitogenesis, tumor growth and invasion [66]. It
is also expressed in the majority of human pituitary adenomas, and its expression parallels that of Ki-67,
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while both are correlated to a more aggressive behavior of pituitary adenomas [67]. PTTG stimulates
fibroblast growth factor 2 (FGF2) and VEGF production, thus further promoting the invasiveness
and angiogenesis of pituitary adenomas, especially prolactinoma and growth-hormone-secreting
adenomas [43,44] (Figure 1).
Figure 3. Physiological and pathophysiological mechanisms of estrogen (E) action on proliferation,
growth and secretion of lactotropic (PRL) cells are probably largely mediated by nuclear estrogen
receptor (ER) α. Membrane G-protein-coupled estrogen receptor 1 (GPER)-mediated estrogen signaling
seems to be more involved in antiproliferative and apoptotic actions in the pituitary and may contribute
to rapid secretion of PRL under physiological conditions. Its expression is under ERα-mediated nuclear
signaling [15,59,68–70].
Pituitary adenomas are generally less vascularized than normal pituitary tissue, though a
significantly higher degree of vasculature, also observed in our estrogenized Orx males (Figure 2), has
been shown in macroprolactinomas when compared with noninvasive microprolactinomas [71]. Male
patients typically have higher serum PRL levels and larger tumor volumes, exerting more aggressive
and/or refractive behavior in comparison with female patients [10,72,73]. Some authors indicate
higher [74], while others lower [11], expression of ERα in prolactinomas from male patients. In our
Orx middle-aged model, a lower nuclear ERα IHC signal was also observed in the anterior pituitaries
upon estradiol treatment (Figure 2).
Wierinckx and associates [15] used the most advanced methods (including transcriptomic,
microarray and comparative genomic hybridization analyses) to examine potential sex-linked
dysregulation in aggressive lactotropic tumors that are less sensitive to dopamine agonists in men.
Aside from low expression of ERα, some genes from the X chromosome (Ctag2, Fgf13 and VEGFD)
and chromosome 19p (STAP2) were found to be upregulated in lactotropic tumors, only in men [15].
Cancer testis antigen (Ctag2), whose expression correlated with various markers of aggressiveness
in male prolactinomas, is implicated in the aggressive behavior of breast cancer [75] and repression
of estrogen signaling [76]. Moreover, the authors [15] hypothesized that upregulated expression of
FGF13 enhanced survival of cancer cells [77] and underlined that not only Vegfd, but a significant
number of proteins involved in promotion of angiogenesis, were upregulated exclusively in male
prolactinomas. Finally, they indicated that chromosome abnormalities, in particular 19p gain, may
underly more aggressive behavior of prolactinoma in men and pointed to the mechanism through
which lower expression of ERα in male prolactinomas may increase the transcript level of STAP2 and
consequently, through interaction with the STAT signaling pathways, contribute to genome instability
and tumor progression [15].
Int. J. Mol. Sci. 2020, 21, 2024 7 of 21
Mitogen-activated protein kinase (MAPK) signaling abnormalities are strongly related with
pituitary adenoma development, and changes in molecules such as ERK, p38, JNK, Ras, Akt, NF-kB
and TNF are identified as the most important [78]. In addition to nuclear receptors, membrane-bound
and G-protein-coupled estrogen receptor 1(GPER), which subsequently activates pathways such as
MAPK, plays an important role in rapid estrogen actions. However, the role of membrane-bound ERs
seems to be rather complex, as antiproliferative [68] and apoptotic [69] actions of estradiol mediated
by these receptors have been reported in the pituitary (Figure 3). Thus, even femtomolar doses of
endogenous 17β- and synthetic 1α-ethinil-estradiol activated MAPK, ERK and JNK pathways in
membrane estrogen receptor-enriched GH3/B6 pituitary tumor cells, though the activation of the p38
MAPK pathway required nanomolar doses of estrogens [69]. Fulvestrant, a pure ER antagonist that
blocks the nuclear ERs, as well as cytoplasmic and membrane-bound ERs [79], significantly suppressed
cell viability and invasion of rat GH3 cells by simultaneous regulation of ERK1/2, JNK1/2 and p38
MAPK signaling pathways [45] (Figure 1). GPER is mainly responsible for the rapid nongenomic effects
of estrogen, which are associated with activation of ERK and AKT, as well as for a rapid increase in
intracellular calcium levels [80,81]. GPER is expressed ubiquitously and has diverse biological effects,
including vascular hypertrophy, regulation of cell growth, migration and apoptotic cell death [82].
However, the estradiol-mediated effect on proliferation of lactotropic cells in primary culture seems
not to be due to GPER signaling [83]. The physiological roles of GPER in the pituitary are still not
completely understood, but it seems to be involved in modulation of secretion of gonadotropins [84]
and PRL [70] (Figure 3). At the same time, expression of the GPER gene is under estrogen-mediated
genomic signaling [70] (Figure 3).
4. Effects of Estradiol on the Cellular Microenvironment in the Anterior Pituitary
Limited data exist on estrogen-induced changes of the cellular microenvironment in the pituitary,
as well as on the tumor microenvironment of pituitary adenomas. The tumor microenvironment
influences tumor behavior and aggressiveness and includes immune cells, fibroblasts, endothelial cells,
extracellular matrix and numerous secreted factors such as cytokines and growth factors.
FS cells also express ERs [85]. This is a heterogeneous cell lineage that serves various functions,
including structural, signaling and a supportive role to hormone-producing cells [86]. Besides their
importance for normal anterior pituitary physiology, their identification in pituitary tumors and the
tumor microenvironment suggests that FS cells may also have some major implications in these tumors,
but the exact roles remain to be elucidated [87].
S100β is generally accepted as a marker gene for FS cells [88]. Comparison of the total number
of S100β-immunopositive cells in the pituitaries of estrogen-sensitive Fischer-344 with the same
parameter in the insensitive Sprague-Dawley rat strain revealed that ovariectomized F344 rats have
significantly more S100β-immunopositive cells than ovariectomized Sprague-Dawley females [89].
The interstrain variation in PRL cell responsiveness to estrogens has also been examined in genetic
studies. Genetic variants that reside within Ept7 (estrogen-induced pituitary tumor, a quantitative
trait locus mapped to rat chromosome 7 that is orthologous to an interval within the 8q24.21 region of
the human genome, associated with risk of numerous cancer types and other common diseases) have
been implicated in lactotropic cell responsiveness to estrogens [90]. In particular, Ept7 locus carries
Myc, a well-known proto-oncogene, and estrogens enhance Myc expression in the rat anterior pituitary
gland [46] (Figure 1).
In addition, FS cells produce numerous cytokines and growth factors, including interleukin-6 (IL-6),
follistatin, basic fibroblast growth factor, transforming growth factor β (TGF β), VEGF and leukemia
inhibitory factor, which all regulate lactotropic cell proliferation and prolactinoma development [47].
The TGFβ1 expression was reduced in human and animal prolactinomas [91,92]. Estradiol inhibits
most of the components of the TGFβ1 system, and this mechanism seems to be of importance with
regard to the balance and negative control of the function of lactotropic cells [40] (Figure 1). Sex-related
differences in the pituitary TGFβ1 system were identified in different models of prolactinoma, with
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the authors proposing that the higher levels of the TGFβ1 system in males may contribute to a
lower proliferation rate in males compared with females, under physiological conditions [93]. The
functional crosstalk between immune signals and the ER at the protein level may be important for
both physiological states and prolactinoma development. Such inter-relation was reported for the
ER, morphogenetic protein-4 (BMF-4), a member of the TGF-β superfamily, and Smad-4 in pituitary
prolactinoma [94].
Aside from the effect of estrogen on FS cells, Fujiwara et al. [95] identified a remarkably increased
number of alternatively activated (M2) macrophages upon diethylstilbestrol application in comparison
with normal pituitaries (Figure 1). Interestingly, recruitment of M2 macrophages was detectable even
before tumor formation, indicating their role in tumorigenesis [95]. Recent study results also indicated
that an increased number of M2 macrophages correlated with microvessel density, indicating their role
in angiogenesis and vasculature modulation in pituitary adenomas [48]. Furthermore, tumor-associated
fibroblasts produce cytokines and may increase tumor aggressiveness and proliferation [96], but the
effect of estrogen on this cell population in the pituitary is still largely unknown.
5. Effects of Estradiol on Stem/Progenitor Cells and Transdifferentiation of Lineage-Related
Hormone-Producing Cells in the Anterior Pituitary
In addition to the effect on proliferative and secretory capacity of already-differentiated lactotropic
cells, estradiol might induce their differentiation from the postnatal pituitary stem/progenitor (SP)
cells [49] (Figure 1). The SP cells are present in both rodent and human pituitary until late adult life
and have preserved their capability to self-renew and differentiate, giving a contribution to all anterior
pituitary lineages [97].
SOX2 is generally accepted as the primary marker for SP cells and is often coexpressed with
SOX9, with partial overlap of S-100β expression [50,51] (Figure 1). Estrogen-induced changes in
S100β-immunofluorescent signal indicates a decreased signal in comparison to Orx middle-aged males
(Figure 4). Our data, together with finding that FS cells coexpress S100β and SOX2, are in line with the
assumption that a subpopulation of FS cells also serves a pool of SP cells [16,51,98]. SOX2+/ SOX9+
cells were reported to proliferate due to the effect of estradiol in vitro, with a predisposition to become
lactotropic and luteinizing cells, with a small number differentiating into GH cells [49] (Figure 1).
However, the number of differentiated cells produced is small, indicating low levels of physiological
turnover, therefore indicating that proliferation of differentiated cells is the most likely source of
pituitary phenotypic plasticity and adaptability to large variations [97].
Su et al. [37] analyzed the expression pattern of tumor stem-like cells isolated from MMQ
rat prolactinoma cells and found that Bcl 2, VegfA, Pten, Jun, Fos, and Apc2 gene expressions were
upregulated and the expression of Myc was downregulated in these cells. The model of cancer
stem cell proposes that a small population of cells with stem-like properties initiates and maintains
tumorigenesis and may be more resistant to therapy than other tumor cells [100,101]. The resistance is
probably due to their often slow cycling, nonproliferative states [102] and/or the expression of ABC
transporters, and high levels of aldehyde dehydrogenases [100].
The occurrence of bi- and multi-hormonal cells in the normal anterior pituitary has been described
both in rodent models and in humans [103,104], indicating a more complex structural organization
associated with cellular expansion, transdifferentiation (functional phenotypic conversion without cell
division), and pituitary homeostasis, physiological plasticity and tumorigenesis [41].
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Figure 4. Representative micrographs of immunofluorescently (IFC) stained anterior pituitary sections
of orchidectomized (Orx) and estradiol-treated orchidectomized (Orx+E) middle-aged rats. Weaker
immunofluorescent signal of S100β, stronger growth hormone (GH; adopted from our previous
publication [99] and reprinted by permission of the Licensors - publishers Springer (Licence number
4774320912101)) and adrenocorticotropic hormone (ACTH) immunofluorescent signal, and unchanged
immunofluorescent signal of subunit β of thyroid-stimulating hormone (TSHβ; adopted from our
previous publication [55] and reprinted by permission of the Licensors - publishers Elsevier (Licence
number 4774000297301)), respectively, are observable after estradiol treatment. All figures were obtained
according to the same procedure described in our earlier papers [55,99]. Briefly, for IFC staining, the
following primary antibodies were applied overnight at 4 ◦C: mouse monoclonal anti-S100β antibody
(Abcam, Cambridge, UK; 1:100), polyclonal rabbit anti–rat TSHβ, GH and ACTH (donation from Dr. A.
F. Parlow, National Institute of Health, Bethesda, MD, USA; dilutions 1:500, 1:200, 1:200, respectively).
Alexa Fluor 488 donkey anti-rabbit IgG (Invitrogen Life technologies, CA, USA; 1:300) was applied as
secondary antiserum for 1 h. The sections were mounted with Mowiol 4–88 (Sigma-Aldrich, St. Louis,
MO, USA). Scale bar is shown in the right corner.
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Pituitary specific-lineage transcription factors are involved in the cell-specific expression and
regulation of the gene products of hormone-producing cells. These transcription factors can also be
used to characterize pituitary tumors such as Pit-1 (Pit-1 lineage including thyrotropic, somatotropic,
and lactotropic cells) or ERα (lactotropic and gonadotropic lineage) [13]. According to the currently
accepted model, Pit-1 positive cells during development differentiated into TSHβ-producing and
GH/PRL dual-expressing somatolactotropic cells [105]. The somatolactotrope precursor then gives
rise to the terminally differentiated somatotropes and lactotrops, which produce high levels of GH
and PRL protein, respectively [106]. Moreover, it was reported that a small population of bihormonal
PRL/GH cells (lacto-somatotrophs) remains present in the pituitaries of adult mice [41,52,53] (Figure 1).
Despite significant transcriptomic similarity, almost 300 genes have been identified to be crucial to the
ability of GH and lactotropic cells to respond to the appropriate physiological signals to secrete their
respective hormones [14].
Bihormonal PRL/ GH cells were more abundant in the pituitary of females than in males, indicating
that transdifferentiation contributes to adaptation of the pituitary toward hormonal fluctuations during
the menstrual (estrous) cycle, pregnancy and lactation [53]. In addition to this, recent single-cell
transcriptomic and other relevant analyses of adult mouse pituitaries demonstrated a multihormonal
cluster of hormone-producing cells that, aside from Pit-1 lineage (PRL, GH and TSHβ), co-expressed
LHβ and proopiomelanocortin, a precursor of ACTH [41] (Figure 1). Cells from this cluster have great
phenotypic plasticity potential, which enables rapid response to physiological demands [41].
Though we have not examined PRL/GH or other bi- and multihormonal modalities in the pituitary,
it is possible that processes of terminal differentiation from SP cells and/or transdifferentiation from
lineage-related cells contributed to lactotropic cell hyperplasia observed in the estrogenized Orx
male rats. Hovewer, the total number of GH-immunopositive cells was not significantly changed
upon estradiol treatment. On the other hand, GH immunofluorescence in the pituitary and serum
GH concentrations were elevated [99], in line with combined PRL and GH secretion phenotype of
prolactinoma (Figure 4 and Table 1).
6. Effects of Estradiol on Pituitary ACTH Cells and Glucocorticoid Homeostasis in Males:
Possible Implication on Prolactinoma Development
It is known that sex differences exist in some aspects of hypothalamus—pituitary-adrenal (HPA)
axis activity. Women are more susceptible to autoimmune disease development and stress-related
psychiatric disorders, while men have a greater risk of infectious diseases and nonreproductive
cancers [107,108], pathologies that more or less include HPA axis involvement. However, organization
of the stress-responsive HPA axis is highly conserved throughout mammalian phylogeny [109], and
there is very little sexual dimorphism in the pattern of ACTH cell gene expression [16].
In estradiol-treated Orx middle-aged rats cytomorphology of ACTH cells was generally preserved
and characterized by elongated or round, sparse ACTH cells that were leaning on the capillaries [110].
Moreover, in addition to increased PRL and GH, concentrations of intrapituitary and serum ACTH
were markedly increased, while circulating corticosterone levels remain unchanged [110], as presented
in Figure 4 and Table 1.
A physiologically relevant dose of estradiol (10 nM) was found to stimulate CRH gene expression
as well as to increase IL-6 mRNA and protein levels [111], which clarifies the agenda of molecular events
underlying the rise of estradiol-caused CRH gene expression in the hypothalamic paraventricular
nucleus (PVN). Considering the role of hypothalamic IL-6 in stimulation of CRH gene expression [112],
it is possible that IL-6 elevation upon estradiol treatment significantly contributes to the CRH secretion.
When it comes to clinical estradiol application in men, it was reported that polyestradiol
phosphate (Estradurin; 80 mg i.m., once a month, during 12 months) did not change circulating
ACTH concentrations in aged prostate cancer patients, neither alone nor in combination with
orchidectomy [113]. In patients with disseminated prostate cancer treated with Estracyt (estradiol
normustine phosphate), either subnormal or low-normal plasma ACTH concentrations followed by
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high cortisol levels were observed [114]. Mental-stress-induced increases in blood ACTH, cortisol and
adrenaline levels were attenuated after estradiol supplementation in aged hypogonadal men [115]. It
has been recently reported that transsexual male patients subjected to estradiol treatment have increased
ACTH and cortisol output in response to CRH [116]. Moreover, the application of estradiol valerate
in transsexual male patients led to initial, moderate decreases of ACTH and cortisol blood levels,
and subsequent significant increases of both parameters, coincident with the time when circulating
estradiol concentrations become nondetectable [117].
Glucocorticoids normally suppress PRL secretion, while it was established that estrogen-induced
pituitary tumors in rats, predominantly composed of proliferating lactotropic cells, express low content
of glucocorticoid receptors (GR) [118]. Binding of radiolabeled, synthetic glucocorticoid dexamethasone
to soluble GR is several times lower in estrogen-induced pituitary tumors than in normal pituitaries [118].
Consequently, glucocorticoid negative feedback on synthesis, and consequently, secretion of PRL
is deficient in pituitary-tumor-bearing rats [118]. Regardless of the blood levels of glucocorticoids
(variable in different studies with estradiol, as stated previously), reduced expression of GR in
estrogen-induced pituitary tumors suggests generally weak glucocorticoid input in this context. Even
ACTH-secreting pituitary tumors express a largely autonomous mode of ACTH secretion that is
supposedly insensitive to physiological negative feedback and glucocorticoid levels [119]. On the
other hand, glucocorticoids stimulate secretion of macrophage migration inhibitory factor (MIF) by
folliculo-stellate cells, macrophages and T lymphocytes. MIF has been identified in the pituitary gland,
and this counter-regulates the inhibitory effects of glucocorticoids on TNFα, IL-1β, IL-6 and IL-8
production [120]. Therefore, attenuated glucocorticoid signaling may actually promote prolactinoma
development and/or progression by affecting its cellular microenvironment. Possible changes in
glucocorticoid signaling that may contribute to prolactinoma progression are illustrated in Figure 5.
Figure 5. Hypothetic role of attenuated glucocorticoid hormone signaling in prolactinoma. Expression
of glucocorticoid receptor (GR) is decreased in estrogen-induced prolactinoma and may contribute
to increased adrenocorticotropic hormone (ACTH) and prolactin (PRL) secretion, as well as to
changes in local secretion of growth factors and interleukins such as mitogen inhibiting factor
(MIF), tumor necrosis factor α (TNFα), interleukins (IL) 1β, 6 and 8, thus promoting “tumor-friendly“
microenvironment [110,118–120].
7. Effects of Estradiol on TSH Cells in Males and Putative Changes in Local Thyroid Hormone
Metabolism and Action in Prolactinomas
Sex steroids affect the feedback response of TSH cells to free thyroid hormone concentrations
in blood diversely in male and female rodents [121,122]. Male rats have higher TSH values and
are more prone to develop thyroid diseases (or even thyroid carcinoma) in response to goitrogenic
agents compared with females [121,122]. In humans, sex-related differences in TSH values are not as
clearly visible as in rodents, but women are more prone to thyroid dysfunctions in comparison with
men. Moreover, clinical results indicate a negative relationship between the free l-triiodothyronine
(T3) resistance index and age in men, while there were no apparent relationships in women [123].
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Species-specific features of the sex-related regulation of pituitary TSH may be explained by differences
in the functional anatomy of thyroid hormone feedback, with a particular emphasis on differential
expression of deiodinase enzyme (Dio). Namely, deiodinase type 1 (Dio 1) is expressed in rat, while
deiodinase type 3 (Dio 3) is expressed in human anterior pituitary. Deiodinase type 2 (Dio 2) is expressed
in TSHβ cells in rats [124], while in humans it seems to be expressed only in FS cells [125,126].
When we tested how pituitary-thyroid-periphery signaling responds to orchidectomy in our
middle-aged rat model, unchanged serum l-thyroxine (T4) and TSH were detected [127]. On the
other hand, liver Dio 1 and pituitary Dio 2 enzyme activities were decreased, which indicated a local
hypothyroid state, in line with altered cytomorphology of thyrotropic cells, which appeared enlarged
and vacuolated, as in hypothyroid states [122]. In addition to this, most recently, specific cell-type
transcriptomic analysis showed that 100% of sex-dominant genes in TSH cells were male-dominant [16].
Our further research confirmed that neither significant change in TSHβ immunofluorescence in the
pituitary, nor serum concentration of TSH, were detected upon estrogenisation of Orx rats [55], as
presented in Figure 4 and Table 1. Similar results were obtained in male-to-female transsexual patients
exposed to long term treatment with antiandrogen plus estrogen [128]. However, pituitary hyperplasia
and increased TSH production together with PRL cell recruitment may also be induced by primary
hypothyroidism, as was noted in some clinical cases [129,130].
It is largely unknown whether genetic and/or environmental alterations in (local) thyroid hormone
metabolism and action may contribute to pituitary adenoma development and its aggressiveness.
However, a large body of evidence suggests that subclinical and clinical hyperthyroidism both increase
the risk of breast and lung cancers [131], and an association exists between prolactinoma development
and family history of these diseases [8]. Deregulation of thyroid hormone metabolism and action may
result in major disturbances of cellular physiology such as those observed in tumorigenesis. Expression
of Dio 2 seems to be variable in pituitary tumors: Dio 2 mRNA levels were increased in different types of
pituitary adenoma, including TSH- and PRL-producing adenomas, with unchanged or lower Dio 1/Dio 2
ratios found among patients with similar types of tumors [132,133]. Thus, it seems probable to assume
that increased expression of Dio2 may lead to increased intrapituitary production of T3. Hypothetic
alterations in thyroid hormone metabolism and action in prolactinoma are presented in Figure 6.
Figure 6. Hypothetic role of enhanced thyroid hormone signaling in prolactinoma. Deiodinase
type 2 (Dio 2) expression in folliculo-stellate cells is increased in prolactinomas, which may lead to
increased production of l-triiodothyronine (T3) and 3,5-T2 (T2) from l-thyroxine (T4) in the pituitary.
T3- thyroid receptor (TR) β complex prevents proteolisis of estrogen receptor (ER) α in the cell nucleus,
while mutated thyroid receptor (mTRβ) binds to pituitary tumor transforming gene (PTTG), thus
preventing its proteolysis. Both T4 and T3 may bind to its membrane integrin αvβ3 receptor and
activate mitogen-activated protein kinase (MAPK) cascade and phosphorylation processes, including
ERα phosphorylation (dashed arrow). Increased concentration of T2, demonstrated in pituitary
adenomas, may contribute to progression of prolactinoma through stimulation of energy metabolism
in mitochondria [132–140].
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In this context, it may be important to know that T3- TRβ receptor complex prevents proteolysis of
estrogen receptor-α (ERα) in lactotropic cells [134], while mutated TRβ receptor, which lost the ability
to bind T3, prevents degradation of PTTG in thyroid cancer [135] (Figure 6). Moreover, nongenomic
thyroid signaling mediated through the membrane integrin αvβ3 receptor [136,137] promotes tumor
cell proliferation and angiogenesis via stimulation of MAPK and phosphorylation processes, including
phosphorylation of ERα [138] (Figure 6). Upregulated expression of αvβ3 occurred in the parenchyma
of a subset of human pituitary adenomas but not in normal pituitaries [136].
To the best of our knowledge, there are still no data regarding the putative association between
changes in thyroid hormone metabolites and the pituitary adenoma or prolactinoma, especially
upon estradiol treatment. As a part of TH metabolism, Dio enzymes are proposed to catalyze the
production of physiologically active 3,5-diiodothyronine (3,5-T2) [139]. 3,5-T2 is present in significant
concentrations in human serum [141] and seems to have important implications in the regulation of
energy metabolism, with a direct effect on mitochondria as the most likely mechanism [139,141–143]
(Figure 6). So far, serum 3,5-T2 concentrations have been associated with some pathophysiological states
in humans, mainly related to glucose and lipid metabolism [144]. This metabolite exerts thyromimetic
activity, suppresses TSH and stimulates GH [145–147], though not as strongly as T3 [139]. Moreover, the
local concentration of 3,5-T2 in human brain tumors and pituitary adenomas is significantly increased
in comparison with nontumoral regions of the human brain [140]. Further experimental research and
analyses are needed to shed more light on this still largely unexplored area.
8. Conclusions
We should be aware that estradiol exerts a rather complex regulatory pattern in the anterior
pituitary, affecting hormone secretion, cell proliferation and death at the same time, as well as the
cellular microenvironment. A significant number of genes implicated in genesis and progression
of prolactinoma, such as Pttg, Myc, MAP kinases, Vegf and other growth factors and cytokines,
are regulated by estrogen signaling in both sexes. Development of macroprolactinomas with
more aggressive features in men in comparison to women may be associated with attenuation
of ERα-mediated control and accumulated chromosomal abnormalities. Symptomatic estrogenization
of men bears a certain risk of tumor development in genetically susceptible patients, with probable effect
on other hormone-producing cells and local hormone signaling. Studies with rodent models should
provide the identification of new molecular targets and additional treatment modalities for patients
with prolactinomas resistant to the classical therapeutic approach. Further examinations of alterations
in local glucocorticoid and thyroid hormone metabolism and actions upon estradiol treatment may
shed more light on tumor microenvironment and energetic pathways in the pituitary adenoma.
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